Total Cases


Total Deaths


Total Recovered


Total Active Cases


New Deaths


New Cases

via nepalitimes04/13/2021

Preparing for a 'No Normal' - Nepali times

Nepali workers from India lining up at the border for health checks this week. Photo: RSS hen the Nepal government clamped a lockdown after only the second case was detected in a student travelling back from France last year, everyone thought it would be for a week or two at most. We have passed the […]

via theshillongtimes04/12/2021

Former Nepal king Gyanendra in India to attend Kumbh - The Shillong Times

New Delhi, April 12: The last king of Nepal, Gyanendra Shah is in India to attend the Kumbh festival. He arrived in the holy city of Haridwar on Sunday to participate in the biggest Hindu festival. King Gyanendra will visit other important temples in the holy city—which lies on the banks of river Ganga. During […]

via wionews04/11/2021

Nepal reports 303 new cases of coronavirus: Health Ministry - WION

Nepal has reported 303 new cases of coronavirus in the last 24 hours, taking the total number of infections in the nation to 280,028, the health ministry said on Sunday.   The nation has also reported 3,040 deaths due to the contagious viral disease so far.  "Nepal has been witnessing a sharp rise in COVID-19 cases in the past one week. As many as 303 new cases of the novel coronavirus infections were detected across the country in the past 24 hours," the Ministry of Health and Population said in a statement.

via english.onlinekhabar04/11/2021

China's restriction on Manasarovar trip takes a toll on Nepali entrepreneurs - Online Khabar (English)

From 2014 to 2019, over 100,000 Indian nationals have been to Mansarovar lake via Nepal. They bring in both money and work for Nepal’s tourism which even thrives in the lean seasons of June – August as each tourist spends at least $1,200 which can go up to as much as $3,000 for the week long trip.

via stopfake.org04/07/2021

Fact-checking in Nepal in the time of pandemic: The spread of the virus opened up a floodgate of misinformation -

By Sanjib Chaudhary, for Global Voices From exposing the misleading social media photos about the recent wildfires to discrediting COVID-19 hoaxes, the South Asia Check group has been actively challenging the spread of disinformation in Nepal. Officially launched on 9 September 2015, the group

via nepalitimes04/06/2021

Nepal braces for its 2nd Covid wave - Nepali times

Nepalis crossing the border into the country last year through the Gauriphanta checkpost in Dhangadi, Far Western Nepal. Photos: DINESH KHABAR ndia reported over 100,000 new cases on a single day for the first time on Monday, putting neighbouring Nepal on high alert. A repeat of what happened exactly a year ago seems likely, as […]

via ch-aviation04/05/2021

Nepal Airlines launches tender for sale of B757 engine, APU - ch-aviation

Most extensive and up to date airline knowledge base: More than 50,000 aircraft, 6,500 airports and 5,000 airlines, access to fleet lists, worldwide airline schedules and route networks, airline management contacts, airline capacity and frequency analysis, airline PSS directory, up to date airline and route network news.

via deccanherald04/13/2021

Nepal chokes on smoke and ash as drought-worsened wildfires rage - Deccan Herald

In the eight years that Basudev Pokharel has worked as a forest guard, he has rarely seen a fire as huge as the one that raged through his village in western Nepal in March. Hundreds of such fires have been spreading across the country since November, in the worst wildfire season Nepal has seen in a decade. The night the blaze reached Pokharel's village of Sungure, in Dang

via daijiworld04/12/2021

Former Nepal king Gyanendra in India to attend Kumbh -

By Rahul Kumar New Delhi, Apr 12: The last king of Nepal, Gyanendra Shah is in India to attend the Kumbh festival. He arrived in the holy city of Haridwar on Sunday to participate in the biggest Hindu festival. King Gyanendra will visit other important temples in the holy city—which lies on the banks of river Ganga.....

via business-standard04/09/2021

Covid-hit Bengaluru FC have task cut out against Tribhuvan Army FC - Business Standard

Read more about Covid-hit Bengaluru FC have task cut out against Tribhuvan Army FC on Business-standard. Hit hard by the Covid-19 pandemic, Bengaluru FC will have their task cut out when they take on Nepal club, Tribhuvan Army FC, in the AFC Cup Qualifiers (Preliminary Stage Two) at the GMC Stadium

via ethnobiomed.biomedcentral04/08/2021

The use of medicinal plants to prevent COVID-19 in Nepal - BMC Blogs Network

Medicinal plants are the fundamental unit of traditional medicine system in Nepal. Nepalese people are rich in traditional medicine especially in folk medicine (ethnomedicine), and this system is gaining much attention after 1995. The use of medicinal plants has increased during the COVID-19 pandemic as a private behavior (not under the control of government). A lot of misinterpretations of the use of medicinal plants to treat or prevent COVID-19 have been spreading throughout Nepal which need to be managed proactively. In this context, a research was needed to document medicinal plants used, their priority of use in society, their cultivation status, and the source of information people follow to use them. This study aimed to document the present status of medicinal plant use and make important suggestion to the concerned authorities. This study used a web-based survey to collect primary data related to medicinal plants used during COVID-19. A total of 774 respondents took part in the survey. The study calculated the relative frequencies of citation (RFC) for the recorded medicinal plants. The relationship between plants recorded and different covariates (age, gender education, occupation, living place, and treatment methods) was assessed using Kruskal-Wallis test and Wilcoxon test. The relationship between the information sources people follow and the respondent characteristics was assessed using chi-square test. The study found that the use of medicinal plants has increased during COVID-19 and most of the respondents recommended medicinal plants to prevent COVID-19. This study recorded a total of 60 plants belonging to 36 families. The leaves of the plants were the most frequently used. The Zingiber officinale was the most cited species with the frequency of citation 0.398. Most of the people (45.61%) were getting medicinal plants from their home garden. The medicinal plants recorded were significantly associated with the education level, location of home, primary treatment mode, gender, and age class. The information source of plants was significantly associated with the education, gender, method of treatment, occupation, living with family, and location of home during the lockdown caused by COVID-19. People were using more medicinal plants during COVID-19 claiming that they can prevent or cure COVID-19. This should be taken seriously by concerned authorities. The authorities should test the validity of these medicinal plants and control the flow of false information spread through research and awareness programs.

via nepalitimes04/07/2021

Despite Covid-19, climbers are back on Everest - Nepali times

amche Bazar, the gateway to Mt Everest, is currently abuzz with climbers and trekkers as they prepare to head towards Base Camp after the pandemic closed Nepal’s tourism for a year. The narrow stone-paved streets of this township at 3,500m are once more filled with trekkers and climbers from all over the world, spending a day […]

via thehimalayantimes04/06/2021

EDITORIAL: Revival of expeditions - The Himalayan Times

With the start of the spring season, the number of foreign tourists arriving in Nepal has increased, allowing the tourism industry and the mountaineering sector to breathe some sigh of relief, both of which have suffered big setbacks since the outbreak of the COVID-19 pandemic last year


Nepal may see spike in COVID-19 cases in June, warns health minister - Yahoo India News

<p>Kathmandu, Apr 5 (PTI) A new wave of coronavirus in Nepal may reach its peak in June if the necessary precautions are not taken in advance, the country’s health minister warned on Monday, as the number of COVID-19 cases reached 278,210 in the Himalayan nation.</p>

via dnaindia04/12/2021

Devotees in Nepal begin celebrating New Year amidst COVID-19 spike - DNA India

Devotees in Nepal begin celebrating New Year amidst COVID-19 spike - Tens of thousands of devotees gathered in Bhaktapur city in Nepal on Sunday to celebrate the arrival of New Year with chariot festival despite the coronavirus pandemic. Devotees flocked to the Taumadhi Square to take part in the "Biska Jatra" fair , where idol of Lord Bhairab was carried to the chariot and devotees were indulged in a tug of war.


Festival to mark arrival of Nepali New year kicks off in Kathmandu amid COVID-19 spike - Yahoo India News

Kathmandu [Nepal], April 11 (ANI): Despite the rising cases of COVID-19 in Nepal, the Taumadhi square of Bhaktapur city on Saturday was packed with revellers and devotees who came here to participate in the annual event Biska Jatra (fair), which signals the arrival of Nepali New Year.

via nepalitimes04/08/2021

1st signs of the 2nd wave in Nepal - Nepali times

Photo: AMIT MACHAMASI epalis had started to heave a sigh of relief with the start of the vaccine drive, but the latest surge in infection rates show there is much to be vigilant about. On 7 April 2021, Kathmandu Valley reported 163 new Covid-19 cases, against the 298 cases across the country. At a first glance, the […]

via who.int04/08/2021

COVAX reaches over 100 economies, 42 days after first international delivery - World Health Organization

The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on 24 February 2021So far, more than 38 million doses of vaccines from manufacturers AstraZeneca, Pfizer-BioNTech and Serum Institute of India (SII) have now been delivered, including 61 economies eligible for vaccines through the Gavi COVAX Advance Market Commitment COVAX aims to supply vaccines to all participating economies that have requested vaccines, in the first half of 2021, despite some delays in planned deliveries for March and April.More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on 24 February 2021.COVAX has now delivered more than 38 million doses across six continents, supplied by three manufacturers, AstraZeneca, Pfizer-BioNTech and the Serum Institute of India (SII). Of the over 100 economies reached, 61 are among the 92 lower-income economies receiving vaccines funded through the Gavi COVAX Advance Market Commitment (AMC).Despite reduced supply availability in March and April – the result of vaccine manufacturers scaling and optimising their production processes in the early phase of the rollout, as well as increased demand for COVID-19 vaccines in India – COVAX expects to deliver doses to all participating economies that have requested vaccines in the first half of the year.“In under four months since the very first mass vaccination outside a clinical setting anywhere in the world, it is tremendously gratifying that the roll-out of COVAX doses has already reached one hundred countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “COVAX may be on track to deliver to all participating economies in the first half of the year yet we still face a daunting challenge as we seek to end the acute stage of the pandemic: we will only be safe when everybody is safe and our efforts to rapidly accelerate the volume of doses depend on the continued support of governments and vaccine manufacturers. As we continue with the largest and most rapid global vaccine rollout in history, this is no time for complacency.”“COVAX has given the world the best way to ensure the fastest, most equitable rollout of safe and effective vaccines to all at-risk people in every country on the planet,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “If we are going to realize this great opportunity, countries, producers and the international system must come together to prioritize vaccine supply through COVAX. Our collective future, literally, depends on it.”"This is a significant milestone in the fight against COVID-19. Faced with the rapid spread of COVID-19 variants, global access to vaccines is fundamentally important to reduce the prevalence of the disease, slow down viral mutation, and hasten the end of the pandemic,” said Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI). “The extraordinary scientific achievements of the last year must now be matched by an unprecedented effort to protect the most vulnerable, so the global community must remain firmly focused on reducing the equity gap in COVID-19 vaccine distribution." “In just a month and a half, the ambition of granting countries access to COVID vaccines is becoming a reality, thanks to the outstanding work of our partners in the COVAX Facility,” said Henrietta Fore, UNICEF Executive Director. “However, this is no time to celebrate; it is time to accelerate. With variants emerging all over the world, we need to speed up global rollout. To do this, we need governments, along with other partners, to take necessary steps to increase supply, including by simplifying barriers to intellectual property rights, eliminating direct and indirect measures that restrict exports of COVID-19 vaccines, and donating excess vaccine doses as quickly as possible.”According to its latest supply forecast, COVAX expects to deliver at least 2 billion doses of vaccines in 2021. In order to reach this goal, the COVAX Facility will continue to diversify its portfolio further, and will announce new agreements with vaccine manufacturers in due course. Furthermore, in March it was announced that the United States government will host the launch event for the 2021 Gavi COVAX AMC Invest Opportunity to catalyze further commitment and support for accelerated access to vaccines for AMC-supported economies. An additional US$ 2 billion is required in 2021 to finance and secure up to a total of 1.8 billion donor-funded doses of vaccines. COVAX is also working to secure additional sourcing of vaccines in the form of dose-sharing from higher income countries.Quotes from donors and partnersPresident of the European Commission Ursula von der Leyen said: “As we continue our common race to speed up safe and effective vaccination everywhere, I want to commend COVAX for having delivered first vaccines to 100 countries in every corner of the world, including some of the most vulnerable warn torn countries like Afghanistan and Yemen. This is a real milestone. Team Europe has strongly invested in COVAX and I urge all partners to support COVAX to make sure no one is left behind”.  Senator the Hon Marise Payne, Minister for Foreign Affairs and Minister for Women, Australia said: “Australia welcomes the progress made by COVAX in COVID-19 vaccine distribution across the world. One hundred countries now have access to life-saving COVID-19 vaccines through COVAX. We are proud to work with global partners to achieve equitable global access to safe and effective vaccines.”Karina Gould, Minister of International Development, Canada and co-chair, COVAX AMC Engagement Group said: “Despite the many challenges it faced, the COVAX Facility has continued to deliver. In just a matter of weeks, it’s been supplying vaccines to 100 countries. This is a milestone we can all be proud of. Now, more than ever, we must continue to work together and support multilateral mechanisms like the COVAX Facility and the ACT-Accelerator.”  Jean-Yves le Drian, Minister of Europe and Foreign Affairs, France said: “One hundred countries have now received safe, WHO-approved vaccines against COVID-19 through the COVAX Facility. France welcomes this crucial step forward, which demonstrates that multilateralism in global health, as well as the spirit of solidarity and responsibility on which it is based, constitutes the most effective response to this pandemic. But the fight against the virus is far from over: we must continue to support COVAX and accelerate equitable access to vaccines in fragile countries, in particular through sharing of vaccine doses. This is what France wants to do, together with its EU and G7 partners.”Dr Gerd Müller, Federal Minister for Economic Cooperation and Development, Germany said: “We either beat the pandemic worldwide or we will not beat it at all. The only way out of the crisis is a global immunization campaign. In order to now be able to vaccinate people quickly, we are using the tried and tested structures of the global vaccine alliance Gavi. Thanks to the vaccination platform COVAX, the structures are in place to provide vaccines for at least 20 per cent of people in developing countries and emerging economies over the course of this year.”Heiko Maas, Minister of Foreign Affairs, Germany said: “The fact that St.Lucia yesterday became the 100th country to be supplied with vaccines via the COVAX platform supported by Germany and the EU, is a milestone on the way out of the pandemic. This progress gives us hope, for we too will only be safe when everyone around the world is safe. Access to vaccines, medicines and tests must not become a geopolitical pawn. Rather, they must be available to all countries in a fair and transparent manner. That’s why we’re committed to COVAX, to a multilateral approach.”Colm Brophy TD, Minister of State for Overseas Development and the Diaspora, Ireland said: “Through our funding to COVAX, Ireland is supporting developing countries, who most need vaccines and can least afford them, secure their share of global supply.”Dag-Inge Ulstein, Minister of International Development, Norway, and Co-chair of the ACT-Accelerator Facilitation Council said: “In less than a year, the world has come together to develop and secure equitable global access to COVID-19 vaccines. That is a huge victory. But the risk of vaccine nationalism is still looming large. Countries and manufactures must prioritize global solutions. It is also crucial that all manufacturers continue to make their vaccines available and affordable to COVAX, so that the global rollout can continue. Countries that have more vaccines than they need should share vaccines through COVAX. I also expect all relevant stakeholders to take action to ensure that the world can produce enough vaccines, at a price that even the poorest countries can afford.”H.E. Dr Tawfig AlRabiah, Minister of Health in Saudi Arabia said: “‘People’s health first’ has been the guiding principle, driving all efforts in the fight against the pandemic - both nationally and globally - to ensure that “No one is left behind”. We in the kingdom are proud contributors to GAVI and the COVAX facility, which has now shipped over 37 million vaccines. This show of solidarity is the cure to fighting COVID-19, and our collective resilience will enable us to overcome any future pandemic we may face.”  Foreign, Commonwealth and Development Office Minister Wendy Morton, United Kingdom said: “From Nigeria to Nepal, COVAX has now delivered life-saving vaccine doses to 100 countries and territories which is a huge achievement and another step towards making us all safe. The UK has played a leading role in achieving equitable access to vaccines by providing £548 million for COVAX early on, which will help to deliver more than one billion doses around the world, as well as lobbying international partners to increase their funding.”United States Secretary of State Antony J. Blinken said: “The United States welcomes the news that COVAX has delivered safe and effective COVID-19 vaccines to 100 countries.  The United States signaled our strong support for COVAX through an initial $2 billion contribution to Gavi.  Through unprecedented partnerships among donors, manufacturers, and participating countries, COVAX has achieved extraordinary milestones in equitably distributing doses to the global community in record time.” Werner Hoyer, President of the European Investment Bank said: “As part of Team Europe the European Investment Bank is pleased to provide EUR 400 million for COVAX, representing the EIB’s largest ever support for global public health. COVAX has already provided vaccines to vulnerable groups and front line workers and brought hope to millions more. COVAX demonstrates the benefit of global cooperation to tackle the shared challenge of COVID. Congratulations to the COVAX team and global partners in 100 countries around the world. Together we are ensuring equitable access to vaccines and together we are directing our efforts towards a global recovery.”Pascal Soriot, AstraZeneca CEO, said: “Today marks a significant milestone in the global fight against the pandemic as 100 countries have received vaccine through COVAX. I am proud that the supply of our vaccine accounts for the vast majority of doses being delivered through COVAX in the first half of this year. Over 37 million doses of our vaccine have been delivered to date which are protecting the most vulnerable populations around the world.  Together with our COVAX partners, we continue to work 24/7 to deliver on our unwavering commitment to broad, equitable and affordable access.”Pfizer Chairman and CEO Albert Bourla said: “Congratulations to everyone who has worked tirelessly to reach this impressive milestone. At Pfizer we are driven every day by the belief that science will win. Through collaboration and commitment, COVAX has brought forth a global solution that helps to bring breakthrough science to everyone, everywhere. We are proud to work together with the facility and all of its partners and remain firmly committed to working toward the shared vision of equitable access for all to end this pandemic.” Sai D. Prasad, President, Developing Countries Vaccines Manufacturing Network (DCVMN) said: “COVAX has made history by ensuring equitable access for COVID-19 vaccines to all countries irrespective of their economic status. The 100th delivery marks a great milestone for COVAX, leading to enhanced deliveries during 2021. We commend the efforts by all partners in COVAX for this achievement. Developed and developing country manufacturers have played a crucial role in product development and large scale manufacturing. In order to meet the requirements of all countries, more partnerships between innovators and manufacturers are required. COVAX’s leadership in COVID-19 vaccines will ensure that we leave no one behind.”Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) & founding partner of ACT-A said: “The timeline is truly impressive; one that is difficult to square with warnings of “catastrophic moral failure”. It’s an innovation success story with the first WHO vaccine approval on 31 December 2021, less than a year after the virus was first shared. It’s a manufacturing success story with the scaling up from zero to one billion doses being produced by April 2021. It is a logistics and country preparedness success story, with 100 countries receiving the vaccines. And last but by no means least, it’s a collaboration and solidarity success story thanks to the commitment from donors and the tireless efforts of the partners of COVAX including the developing and the developed world manufacturers. The COVAX public private partnership and political leadership to equitably share surplus vaccines are the best guarantees we have that people who need the vaccine will get it whenever they live, fast enough to outpace the virus’ mutations.”Notes to editorsThe list of 102 Facility participants (as of 14h CET, 8 April) that have received a combined total of 38,392,540 doses of COVAX-delivered vaccines so far is as follows (in alphabetical order):Afghanistan, Albania, Algeria, Andorra, Angola, Argentina, Armenia, Azerbaijan, Bahamas, Bahrain, Barbados, Belize, Benin, Bermuda, Bolivia (Plurinational State of), Bosnia and Herzegovina, Botswana, Brazil, Brunei Darussalam, Cabo Verde, Cambodia, Canada, Colombia, Congo (DRC), Costa Rica, Côte d'Ivoire, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Eswatini, Ethiopia, Fiji, Gambia, Georgia, Ghana, Grenada, Guatemala, Guyana, Honduras, India, Indonesia, Iran (Islamic Republic of), Iraq, Jamaica, Jordan, Kenya, Kosovo, Lao People's Democratic Republic, Lebanon, Lesotho, Liberia, Malawi, Maldives, Mali, Mauritius, Mongolia, Montenegro, Morocco, Mozambique, Nauru, Nepal, Nicaragua, Nigeria, North Macedonia, Oman, Palestine, Paraguay, Peru, Philippines, Qatar, Republic of Korea, Republic of Moldova, Rwanda, Samoa, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Sierra Leone, Solomon Islands, Somalia, South Sudan, Sri Lanka, St. Lucia*, Sudan, Suriname, Taiwan, Tajikistan, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Tuvalu, Uganda, Uruguay, Uzbekistan, Viet Nam, Yemen. *100th Facility participant to receive a COVAX delivery About COVAX COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-convened by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance Gavi) and the World Health Organization (WHO) – working in partnership with UNICEF as key implementing partner, developed and developing country vaccine manufacturers, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.CEPI’s role in COVAXCEPI is leading on the COVAX vaccine research and development portfolio, investing in R&D across a variety of promising candidates, with the goal to support development of three safe and effective vaccines which can be made available to countries participating in the COVAX Facility. As part of this work, CEPI has secured first right of refusal to potentially over one billion doses for the COVAX Facility to a number of candidates, and made strategic investments in vaccine manufacturing, which includes reserving capacity to manufacture doses of COVAX vaccines at a network of facilities, and securing glass vials to hold 2 billion doses of vaccine. CEPI is also investing in the ‘next generation’ of vaccine candidates, which will give the world additional options to control COVID-19 in the future.  Gavi’s role in COVAXGavi is leading on procurement and delivery at scale for COVAX: coordinating the design, implementation and administration of the COVAX Facility and the COVAX AMC and working with its Alliance partners UNICEF and WHO, along with governments, on country readiness and delivery. As part of this role, Gavi hosts the Office of the COVAX Facility to coordinate the operation and governance of the mechanism as a whole, manages relationships with Facility participants, and negotiates advance purchase agreements with manufacturers of promising vaccine candidates on behalf of the 190 economies participating in the COVAX Facility. It also coordinates design, operation and fundraising for the COVAX AMC that supports 92 lower-income economies, including a no-fault compensation mechanism that will be administered by WHO. As part of this work, Gavi supports governments and partners on ensuring country readiness, providing funding and oversight of UNICEF procurement of vaccines as well as partners’ and governments work on readiness and delivery. This includes support for cold chain equipment, technical assistance, syringes, vehicles, and other aspects of the vastly complex logistical operation for delivery.WHO’s role in COVAXWHO has multiple roles within COVAX: It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery. Its Strategic Advisory Group of Experts (SAGE) on Immunization develops evidence-based immunization policy recommendations. Its Emergency Use Listing (EUL) / prequalification programmes ensure harmonized review and authorization across member states. It provides global coordination and member state support on vaccine safety monitoring. It developed the target product profiles for COVID-19 vaccines and provides R&D technical coordination. WHO leads, together with UNICEF, the Country Readiness and Delivery workstream, which provides support to countries as they prepare to receive and administer vaccines. Along with Gavi and numerous other partners working at the global, regional, and country-level, the CRD workstream provides tools, guidance, monitoring, and on the ground technical assistance for the planning and roll-out of the vaccines. Along with COVAX partners, WHO has developed a no-fault compensation scheme as part of the time-limited indemnification and liability commitments.UNICEF’s role in COVAXUNICEF is leveraging its experience as the largest single vaccine buyer in the world and working with manufacturers and partners on the procurement of COVID-19 vaccine doses, as well as freight, logistics and storage. UNICEF already procures more than 2 billion doses of vaccines annually for routine immunization and outbreak response on behalf of nearly 100 countries. In collaboration with the PAHO Revolving Fund, UNICEF is leading efforts to procure and supply doses of COVID-19 vaccines for COVAX. In addition, UNICEF, Gavi and WHO are working with governments around the clock to ensure that countries are ready to receive the vaccines, with appropriate cold chain equipment in place and health workers trained to dispense them. UNICEF is also playing a lead role in efforts to foster trust in vaccines, delivering vaccine confidence communications and tracking and addressing misinformation around the world.About ACT-AcceleratorThe Access to COVID-19 Tools ACT-Accelerator, is a new, ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. It was set up in response to a call from G20 leaders in March 2020 and launched by the WHO, European Commission, France and The Bill & Melinda Gates Foundation in April 2020. The ACT-Accelerator is not a decision-making body or a new organization, but works to speed up collaborative efforts among existing organizations to end the pandemic. It is a framework for collaboration that has been designed to bring key players around the table with the goal of ending the pandemic as quickly as possible through the accelerated development, equitable allocation, and scaled up delivery of tests, treatments and vaccines, thereby protecting health systems and restoring societies and economies in the near term. It draws on the experience of leading global health organizations which are tackling the world’s toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to ensure all people have access to all the tools needed to defeat COVID-19 and to work with unprecedented levels of partnership to achieve it.The ACT-Accelerator has four areas of work: diagnostics, therapeutics, vaccines and the health system connector. Cross-cutting all of these is the workstream on Access & Allocation.

via cnbctv1804/06/2021

COVID-19: EU provides debt relief to Nepal - CNBCTV18

Nepal has received a debt service relief amounting to Nepali Rupees 582 million through a trust set up by the IMF to help the poorest and the most vulnerable countries to address the COVID-19 pandemic and other disasters. Nepal is among 28 other countries receiving the debt relief, according to a statement issued by the EU Nepal Office.Get latest Healthcare online at

via english.onlinekhabar04/06/2021

Nepal among 28 countries to receive debt service relief from EU - Online Khabar (English)

Nepal is among 28 countries to receive a debt service relief amounting to Euro 4.299 million (approximately Rs 582 million) through a European Union contribution of Euro 183 million to the Catastrophe Containment Relief Trust (CCRT) set up by the International Monetary Fund (IMF), the EU Delegation to Nepal informs.